Michael Aiello of Weil, Gotshal & Manges remembers a time, as recently as ten years ago, when some investment banks wouldn’t touch a hostile bid. “They were buddies with corporations, so they didn’t want to launch a hostile bid against them,” he says. But these daysspurred by an uncertain economy, deep corporate cash reserves, and lack of organic growthgoing hostile has gone mainstream.
“Everybody does it now,” says Aiello, who represented pharmaceutical giant Sanofi-Aventis in its $18.5 billion hostile bid for biotech firm Genzyme Corporation last year. (Sanofi ended up acquiring Genzyme after upping its bid to $20.1 billion.)
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
